Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PolyPid ( (PYPD) ) has shared an announcement.
PolyPid Ltd. announced the appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks, who has been on the company’s Board of Directors since November 2023, will lead the medical strategy following the positive Phase 3 SHIELD II trial results. Her leadership is expected to be crucial as the company prepares for the New Drug Application submission for D-PLEX100 and advances its pipeline, including a new GLP-1 program. This strategic appointment is seen as a pivotal move for PolyPid, enhancing its industry positioning and potentially benefiting stakeholders by driving the company’s innovative solutions for unmet medical needs in surgical care, oncology, and metabolic diseases.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology allows for the precise delivery of drugs over extended periods, ranging from days to months. PolyPid is advancing its lead product candidate, D-PLEX100, aimed at preventing abdominal colorectal surgical site infections, with a New Drug Application expected in early 2026. The company also has a pipeline targeting oncology, obesity, and diabetes.
Average Trading Volume: 516,358
Technical Sentiment Signal: Sell
Current Market Cap: $32.92M
See more insights into PYPD stock on TipRanks’ Stock Analysis page.